Can thalidomide improve outcome in patients with multiple myeloma?

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Munshi NC and Anderson KC (2005) To transplant or not to transplant? Blood 106: 3687–3688

  2. 2

    Singhal S et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565–1571

  3. 3

    Richardson P et al. (2004) Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 79: 875–882

  4. 4

    Richardson PG et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063–3067

  5. 5

    Rajkumar SV et al. (2006) Phase III clinical trial of thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24: 431–436

  6. 6

    Attal M et al. ((2006) Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood Jul 27 [Epub ahead of print]

  7. 7

    Barlogie B et al. (2006) Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107: 2633–2638

  8. 8

    Palumbo A et al. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367: 825–831

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Correspondence to Kenneth C Anderson.

Ethics declarations

Competing interests

PG Richardson is on the Advisory Board and Speakers' Bureau for Celgene Corporation, and for Millennium Pharmaceuticals. CS Mitsiades is a consultant and receives honoraria from Millennium Pharmaceuticals, Novartis Pharmaceuticals, Bristol-Myers Squibb and Merck & Co. NC Munshi is on the Advisory Board and Speakers' Bureau for Celgene Corporation, Millennium Pharmaceuticals and Novartis Pharmaceuticals. KC Anderson is a consultant and receives honoraria and research support from Celgene Corporation, Millennium Pharmaceuticals and Novartis Pharmaceuticals.

Rights and permissions

Reprints and Permissions

About this article

Further reading